Vials

PT-141 10mg

Name: PT-141 10mg
Brand: Quanta Pharmaceuticals

Bremelanotide, a CNS-acting melanocortin agonist studied for arousal pathways in both sexes.

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH), derived from the parent compound melanotan-2 after researchers observed unrelated arousal effects during early tanning-peptide trials. Unlike peripheral vascular compounds, it acts centrally on melanocortin receptors in the brain. As Bremelanotide (brand name Vyleesi), it received FDA approval on 21 June 2019 for acquired, generalised hypoactive sexual desire disorder (HSDD) in premenopausal women, self-administered via autoinjector at least 45 minutes before anticipated activity. Clinical trial data behind that approval showed a real but modest effect: roughly 25% of treated patients reported a clinically meaningful increase in desire score, versus about 17% on placebo. Independent lab testing confirmed the finished vial at 99% purity with an actual content of 10.06mg against the 10mg label claim.

Verify a product

Specifications

Peptide

PT-141

Also Known As

Bremelanotide, Vyleesi

Class

Melanocortin Agonist

Dosage

10mg/vial

Purity

99%

Verified Content

10.06mg

Sequence

7 Amino Acids

Form

Lyophilised

Half-Life

~2.7 hours

Storage

2-8°C

Research Benefits

Central nervous system mechanism — Acts directly on brain melanocortin receptors, distinct from peripheral vascular compounds.
FDA-approved precedent — Approved in 2019 as Bremelanotide (Vyleesi) for premenopausal HSDD, with roughly 25% of patients reporting a meaningful desire-score increase versus 17% on placebo.
MC3R/MC4R activation — Selectively activates melanocortin receptor subtypes in the hypothalamus and limbic system.
Short, defined activity window — A ~2.7 hour half-life allows precisely timed research windows.
Vascular-independent action — CNS-mediated mechanism means research applicability doesn't depend on vascular or endothelial status.

How It Works

PT-141 acts as an agonist at the MC3 and MC4 melanocortin receptors, densely expressed in the hypothalamus, limbic system, and other central regions involved in arousal, motivation, and reward. Unlike PDE5-inhibitor compounds, which act peripherally on the vascular system, PT-141 crosses the blood-brain barrier and acts on neural pathways directly, generating the upstream signal itself rather than enabling a vascular response to an existing stimulus.

This CNS mechanism is what distinguishes PT-141's research profile, particularly in populations or models where vascular-acting compounds are unsuitable or where the pathway of interest is neural and motivational rather than purely vascular.

⚠ For Research Use Only

This product is supplied strictly for in-vitro laboratory and preclinical research use. It is not a drug, food, dietary supplement, or cosmetic, and is not intended for human or animal consumption, diagnosis, treatment, or prevention of any disease. PT-141 10mg must be handled only by qualified individuals trained in proper laboratory safety procedures.

By purchasing, the buyer confirms this product is being acquired for legitimate research purposes and assumes full responsibility for its handling, storage, and use in compliance with all applicable local, national, and international laws.